Ralf Kettenhofen advances industrial‑scale iPSC platforms and cardiac safety screening. He contributed to building the EBiSC biobank and EBiSC2 ($46M+) to supply quality‑controlled lines and pre‑differentiated cells through standardized 3D bioprocesses and high‑throughput, animal‑use alternatives.